Nosocomial spread of multidrug-resistant group B streptococci with reduced penicillin susceptibility belonging to clonal complex 1

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 4, 2012, Pages 849-856

  Nagano, Noriyuki ^a,b   Nagano, Yukiko ^a   Toyama, Masami ^a,b   Kimura, Kouji ^a,c   Tamura, Takashi ^d   Shibayama, Keigo ^a   Arakawa, Yoshichika ^a,c  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b Funabashi Municipal Medical Center   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Sassa General Hospital   (Japan)

Author keywords

lactams; Fluoroquinolones; Group B Streptococcus; Horizontal transmission; Macrolides

Indexed keywords

AMPICILLIN; CEFAZOLIN; CEFDITOREN; CEFEPIME; CEFIXIME; CEFOTAXIME; CEFOTIAM; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; ERYTHROMYCIN; HABEKACIN; LEVOFLOXACIN; LINCOSAMIDE; MACROLIDE; MEROPENEM; PENICILLIN BINDING PROTEIN; PENICILLIN G; PROTEIN PARC; QUINOLONE; QUINOLONE DERIVATIVE; SULPERAZON; SULTAMICILLIN; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG; VANCOMYCIN;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CLINICAL ARTICLE; FEMALE; HOSPITAL INFECTION; HUMAN; MALE; MULTIDRUG RESISTANCE; NONHUMAN; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; STREPTOCOCCUS AGALACTIAE;

AGED; AGED, 80 AND OVER; BACTERIAL PROTEINS; CROSS INFECTION; DNA, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MULTILOCUS SEQUENCE TYPING; PENICILLIN RESISTANCE; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE;

EID: 84858674197     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr546     Document Type: Article

References (32)

1. Kimura K, Suzuki S, Wachino J et al. First molecular characterization of group B streptococci with reduced penicillin susceptibility. Antimicrob Agents Chemother 2008; 52: 2890-7.
2. Nagano N, Nagano Y, Kimura K et al. Genetic heterogeneity in pbp genes among clinically isolated group B streptococci with reduced penicillin susceptibility. Antimicrob Agents Chemother 2008; 52: 4258-67.
3. Kimura K, Wachino J, Kurokawa H et al. Practical disk diffusion test for detecting group B Streptococcus with reduced penicillin susceptibility. J Clin Microbiol 2009; 47: 4154-7.
4. Dahesh S, Hensler ME, Van Sorge NM et al. Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to β-lactam antibiotics. Antimicrob Agents Chemother 2008; 52: 2915-8.
5. Gaudreau C, Lecours R, Ismaïl J et al. Prosthetic hip joint infection with a Streptococcus agalactiae isolate not susceptible to penicillin G and ceftriaxone. J Antimicrob Chemother 2010; 65: 594-5.
6. Longtin J, Vermeiren C, Shahinas D et al. Novel mutations in a patient isolate of Streptococcus agalactiae with reduced penicillin susceptibility emerging after long term oral suppressive therapy. Antimicrob Agents Chemother 2011; 55: 2983-5.
7. Castor ML, Whitney CG, Como-Sabetti K. Antibiotic resistance patterns in invasive group B streptococcal isolates. Infect Dis Obstet Gynecol 2008; 2008: 727505.
8. Phares CR, Lynfield R, Farley MM et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA 2008; 299: 2056-65.
9. Ministry of Health Labour and Welfare. The Japan Nosocomial Infections Surveillance. http://www.nih-janis.jp/ (2 September 2011, date last accessed).
10. Biedenbach DJ, Toleman MA, Walsh TR et al. Characterization of fluoroquinolone-resistant beta-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY Antimicrobial Surveillance Program (1997-2004). Diagn Microbiol Infect Dis 2006; 55: 119-27.
11. Kawamura Y, Fujiwara H, Mishima N et al. First Streptococcus agalactiae isolates highly resistant to quinolones, with point mutations in gyrA and parC. Antimicrob Agents Chemother 2003; 47: 3605-9.
12. Miro E, Rebollo M, Rivera A et al. Streptococcus agalactiae highly resistant to fluoroquinolones. Enferm Infecc Microbiol Clin 2006; 24: 562-3.
13. Wehbeh W, Rojas-Diaz R, Li X et al. Fluoroquinolone-resistant Streptococcus agalactiae: epidemiology and mechanism of resistance. Antimicrob Agents Chemother 2005; 49: 2495-7.
14. Wu H, Janapatla R, Ho Y et al. Emergence of fluoroquinolone resistance in group B streptococcal isolates in Taiwan. Antimicrob Agents Chemother 2008; 52: 1888-90.
15. Murayama SY, Seki T, Sakata H et al. Capsular type and antibiotic resistance in Streptococcus agalactiae isolates from patients, ranging from newborns to the elderly, with invasive infections. Antimicrob Agents Chemother 2009; 53: 2650-3.
16. Granlund M, Axemo P, Bremme K et al. Antimicrobial resistance in colonizing group B Streptococci before the implementation of a Swedish intrapartum antibiotic prophylaxis program. Eur J Clin Microbiol Infect Dis 2010; 29: 1195-201.
17. Sadowy E, Matynia B, Hryniewicz W. Population structure, virulence factors and resistance determinants of invasive, non-invasive and colonizing Streptococcus agalactiae in Poland. J Antimicrob Chemother 2010; 65: 1907-14.
18. Nagano N, Kimura K, Nagano Y et al. Molecular characterization of group B streptococci with reduced penicillin susceptibility recurrently isolated from a sacral decubitus ulcer. J Antimicrob Chemother 2009; 64: 1326-8.
19. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Eighth Edition: Approved Standard M7-A8. CLSI, Wayne, PA, USA, 2009.
20. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-First Informational Supplement M100-S21. CLSI, Wayne, PA, USA, 2011.
21. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22: 4673-80.
22. Gigax SE, Schuyler JA, Kimmel LE et al. Erythromycin and clindamycin resistance in group B streptococcal clinical isolates. Antimicrob Agents Chemother 2006; 50: 1875-7.
23. Marimón JM, Valiente A, Ercibengoa M et al. Erythromycin resistance and genetic elements carrying macrolide efflux genes in Streptococcus agalactiae. Antimicrob Agents Chemother 2005; 49: 5069-74.
24. Tenover FC, Arbeit RD, Goering RV et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33: 2233-9.
25. Jones N, Bohnsack JF, Takahashi S et al. Multilocus sequence typing system for group B Streptococcus. J Clin Microbiol 2003; 41: 2530-6.
26. Weigel LM, Anderson GJ, Facklam RR. Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45: 3517-23.
27. Verani JR, McGee L, Schrag SJ. Prevention of perinatal group B streptococcal disease: revised guidelines from CDC. MMWR Recommend Rep 2010; 59 (RR-10): 1-32.
28. Brenciani A, Bacciaglia A, Vecchi M et al. Genetic elements carrying erm(B) in Streptococcus pyogenes, and association with tet(M) tetracycline resistance gene. Antimicrob Agents Chemother 2007; 51: 1209-16.
29. Varaldo PE, Montanari MP, Giovanetti E. Genetic elements responsible for erythromycin resistance in streptococci. Antimicrob Agents Chemother 2009; 53: 343-53.
30. Kimura K, Nagano N, Nagano Y et al. Predominance of sequence type 1 group with serotype VI among group B streptococci with reduced penicillin susceptibility identified in Japan. J Antimicrob Chemother 2011; 66: 2460-4.
31. Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis 1992; 15: 77-83.
32. Reinert RR. The antimicrobial resistance profile of Streptococcus pneumoniae. Clin Microbiol Infect 2009; 15 Suppl 3: 7-11.